LWMI
CRSP icon

Legacy Wealth Management (Idaho)’s CRISPR Therapeutics CRSP Stock Holding History

Legacy Wealth Management (Idaho)’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4
Closed -$191 – 353
2026
Q1 		$191 Sell
4
-7
-64% -$369 ﹤0.01% 990
2025
Q4 		$577 Buy
11
+7
+175% +$419 ﹤0.01% 809
2025
Q3 		$260 Hold
4
– – ﹤0.01% 726
2025
Q2 		$195 Hold
4
– – ﹤0.01% 708
2025
Q1 		$137 Hold
4
– – ﹤0.01% 788
2024
Q4 		$159 Hold
4
– – ﹤0.01% 721
2024
Q3 		$200 Buy
+4
New +$203 ﹤0.01% 668

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Legacy Wealth Management (Idaho)'s CRSP Position: Q2 2026 in Review

Legacy Wealth Management (Idaho) sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 4 shares — an estimated $191 sold.

Legacy Wealth Management (Idaho) first reported a position in CRSP in Q3 2024 and held it in 7 quarters. The position peaked at $577 in Q4 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Legacy Wealth Management (Idaho) reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Legacy Wealth Management (Idaho) sold 4 CRISPR Therapeutics shares in Q2 2026, an estimated $191.
  • Legacy Wealth Management (Idaho) first reported a position in CRISPR Therapeutics in Q3 2024 and held it in 7 quarters.
  • Legacy Wealth Management (Idaho)'s CRISPR Therapeutics position peaked at $577 in Q4 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Legacy Wealth Management (Idaho)'s 13F filing for Q2 2026, filed 13 Aug 2026.